AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00461-08v1
52/8/2915    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Dahesh, S.
Right arrow Articles by Beall, B. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahesh, S.
Right arrow Articles by Beall, B. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2008, p. 2915-2918, Vol. 52, No. 8
0066-4804/08/$08.00+0     doi:10.1128/AAC.00461-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam Antibiotics{triangledown}

Samira Dahesh,1,{dagger} Mary E. Hensler,1,{dagger} Nina M. Van Sorge,1 Robert E. Gertz Jr.,3 Stephanie Schrag,3 Victor Nizet,1,2 and Bernard W. Beall3*

Division of Pharmacology and Drug Discovery, Department of Pediatrics,1 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California,2 Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia3

Received 7 April 2008/ Returned for modification 27 May 2008/ Accepted 29 May 2008

Beta-lactam antibiotics (BLAs) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x.

* Corresponding author. Mailing address: CDC/NCIRD/DBD, 1600 Clifton Rd., NE, MS C02, Atlanta, GA 30333. Phone: (404) 639-1237. Fax: (404) 639-4215. E-mail: BBEALL{at}cdc.gov

{triangledown} Published ahead of print on 9 June 2008.

{dagger} These authors contributed equally.

Antimicrobial Agents and Chemotherapy, August 2008, p. 2915-2918, Vol. 52, No. 8
0066-4804/08/$08.00+0     doi:10.1128/AAC.00461-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.